Point72 Asset Management Lp Decreased Karyopharm Therapeutics (KPTI) Stake By $18.12 Million; KMG Chemicals (KMG)’s Sentiment Is 1.65

May 18, 2018 - By Winifred Garcia

KMG Chemicals, Inc. (NYSE:KMG) Logo

Point72 Asset Management Lp decreased Karyopharm Therapeutics Inc (NASDAQ:KPTI) stake by 41.57% reported in 2018Q1 SEC filing. Point72 Asset Management Lp sold 1.39M shares as Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s stock rose 36.94%. The Point72 Asset Management Lp holds 1.96 million shares with $26.28M value, down from 3.35M last quarter. Karyopharm Therapeutics Inc now has $1.20B valuation. The stock increased 4.72% or $0.9 during the last trading session, reaching $19.98. About 503,479 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 18, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

KMG Chemicals Inc (KMG) investors sentiment increased to 1.65 in Q4 2017. It’s up 0.70, from 0.95 in 2017Q3. The ratio is positive, as 84 institutional investors increased and started new positions, while 51 reduced and sold their stock positions in KMG Chemicals Inc. The institutional investors in our database now possess: 11.87 million shares, up from 8.47 million shares in 2017Q3. Also, the number of institutional investors holding KMG Chemicals Inc in top ten positions increased from 2 to 4 for an increase of 2. Sold All: 21 Reduced: 30 Increased: 49 New Position: 35.

The stock increased 0.08% or $0.06 during the last trading session, reaching $68.43. About 41,860 shares traded. KMG Chemicals, Inc. (KMG) has risen 41.92% since May 18, 2017 and is uptrending. It has outperformed by 30.37% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 15 sales for $28.06 million activity.

KMG Chemicals, Inc., through its subsidiaries, makes, formulates, and distributes specialty chemicals worldwide. The company has market cap of $1.06 billion. The companyÂ’s Electronic Chemicals segment is involved in the sale of high purity and ultra purity wet process chemicals primarily to clean and etch silicon wafers in the production of semiconductors. It has a 21.45 P/E ratio. This segmentÂ’s products include sulfuric, phosphoric, and nitric and hydrofluoric acids; ammonium hydroxide; hydrogen peroxide; isopropyl alcohol; other specialty organic solvents; and various blends of chemicals.

Analysts await KMG Chemicals, Inc. (NYSE:KMG) to report earnings on June, 8. They expect $0.87 earnings per share, up 64.15% or $0.34 from last year’s $0.53 per share. KMG’s profit will be $13.49 million for 19.66 P/E if the $0.87 EPS becomes a reality. After $1.04 actual earnings per share reported by KMG Chemicals, Inc. for the previous quarter, Wall Street now forecasts -16.35% negative EPS growth.

Trigran Investments Inc. holds 8.29% of its portfolio in KMG Chemicals, Inc. for 559,352 shares. Bard Associates Inc owns 57,120 shares or 1.81% of their US portfolio. Moreover, Redwood Investments Llc has 1.76% invested in the company for 378,242 shares. The Massachusetts-based Ironwood Investment Management Llc has invested 1.31% in the stock. Globeflex Capital L P, a California-based fund reported 47,261 shares.

Since December 11, 2017, it had 0 buys, and 29 sales for $3.19 million activity. $91,553 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were sold by Shacham Sharon. $42,525 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Mirza Mansoor Raza. Kauffman Michael sold $167,747 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, May 7. 2,500 shares were sold by Primiano Christopher Brett, worth $37,527.

Point72 Asset Management Lp increased Vulcan Matls Co (NYSE:VMC) stake by 1.17 million shares to 1.20 million valued at $137.50M in 2018Q1. It also upped Quanta Svcs Inc (Call) (NYSE:PWR) stake by 850,300 shares and now owns 950,300 shares. S&P Global Inc (Put) () was raised too.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 38 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by Leerink Swann given on Tuesday, May 1. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, May 15. The rating was downgraded by Bank of America on Tuesday, March 15 to “Underperform”. The firm has “Outperform” rating given on Tuesday, June 28 by Robert W. Baird. Canaccord Genuity initiated Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Tuesday, December 22 with “Buy” rating. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Monday, September 11. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Robert W. Baird on Thursday, March 15. The company was maintained on Friday, March 2 by RBC Capital Markets. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Tuesday, August 8 by Canaccord Genuity. The rating was maintained by Cantor Fitzgerald on Monday, April 30 with “Buy”.

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.94, from 2.5 in 2017Q3. It dived, as 4 investors sold KPTI shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Point72 Asia (Hong Kong) stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Sg Americas Secs Ltd Liability stated it has 10,094 shares or 0% of all its holdings. Manufacturers Life The owns 26,729 shares. Tekla Cap Management Ltd Limited Liability Company invested in 0% or 20 shares. State Common Retirement Fund reported 0% stake. Wellington Mngmt Grp Llp holds 6.04 million shares or 0.01% of its portfolio. Sandy Spring Commercial Bank invested in 0% or 3,000 shares. Tcw Group Inc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). C Worldwide Group A S owns 16,048 shares for 0% of their portfolio. Fmr Lc holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 3.98 million shares. 118,430 were accumulated by Alliancebernstein Limited Partnership. Thomas J Herzfeld Advisors invested 0.01% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Iguana Healthcare Mngmt Ltd Limited Liability Company invested 1.88% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Citigroup Inc holds 3,541 shares or 0% of its portfolio. Metropolitan Life accumulated 11,177 shares or 0% of the stock.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.20 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

POINT72 was founded by Steven Cohen and is a family office which makes uses of both quantitative and fundamental analysis approach. Cohen is a billionaire and one of the most famous traders. His wealth is estimated of being around $8 Billion. The return from his business in the last 20 years has been of about 20%+ annually.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>